A personalized Moderna cancer vaccine, combined with collaborator Merck's biggest-selling drug, cut the risk of death or recurrence of the lethal melanoma skin cancer by 44% — Moderna mRNA Melanoma Vaccine Succeeds in Combination With Merck Drug December 13th, 2022 💊

>"The outcome “exceeds our expectations and the threshold for excitement from a randomized phase 2 proof-of-concept trial,” SVB Securities analysts said in a note to clients."